📚 Part of the OBX-319 Regulatory Dossier — Reader's Guide. This article shows the live document; edits to the source appear here automatically.

---

Investigator's Brochure (OBX-319)

Document ID: IB
Version: 1.0
Change History: 1.0 — Initial issue.
Standard(s): ICH E6(R3)

Investigator's Brochure — OBX-319

OBX-319 is a humanized, bispecific IgG1 monoclonal antibody that simultaneously engages CD19 and CD20 on the surface of B lymphocytes, producing broad and durable B-cell depletion across the pre-B through memory-B compartments. By co-targeting two independently regulated B-lineage antigens, OBX-319 is designed to deplete cells that may escape depletion by conventional single-antigen (anti-CD20) therapy, including CD20-low and CD19-restricted precursor and plasmablast populations implicated in the pathogenesis of systemic lupus erythematosus (SLE). The intended indication is moderate-to-severe active SLE on a background of standard-of-care immunosuppression.

The drug substance is produced by recombinant expression in a Chinese hamster ovary (CHO) cell line and purified by a platform process comprising Protein A affinity capture followed by orthogonal polishing chromatography, low-pH viral inactivation, and nanofiltration. The molecule retains a native, effector-competent IgG1 Fc, which contributes to depletion through antibody-dependent cellular cytotoxicity (ADCC), complement-dependent cytotoxicity (CDC), and antibody-dependent cellular phagocytosis (ADCP), in addition to direct pro-apoptotic signalling. The product is formulated as a preservative-free solution for subcutaneous (SC) injection. Control of the drug substance and drug product follows ICH Q6B (specifications, including identity, purity/impurities, charge and size heterogeneity, glycosylation, and potency by Fc-effector and binding bioassays), ICH Q5A(R2) (viral safety of the CHO-derived process), and ICH Q5C (stability). Nonclinical safety characterization follows ICH S6(R1) for biotechnology-derived pharmaceuticals. The product is being developed for licensure as a Biologics License Application under 21 CFR Part 601.

4 Nonclinical Studies

OBX-319 is a bispecific monoclonal antibody. Nonclinical pharmacology, PK (cynomolgus monkey as the sole pharmacologically relevant species (no rodent cross-reactivity)), and toxicology support the clinical doses; Safety margins are expressed as the ratio of systemic exposure (AUC/Cmax) at the NOAEL in the cynomolgus monkey to the projected human exposure at the clinical dose levels evaluated in the trial.

Primary pharmacology. In vitro, OBX-319 bound human CD19 and CD20 with high affinity and mediated concentration-dependent B-cell killing through ADCC, CDC, and ADCP, with direct depletion confirmed against primary human B cells and B-lymphoma lines. The dual-targeting design conferred depletion of antigen-heterogeneous B-cell populations, including cells expressing low levels of either antigen. In the cynomolgus monkey, single and repeat SC administration produced rapid, near-complete depletion of circulating CD19/CD20 B cells with corresponding reductions in splenic and lymph-node B-cell content; depletion was pharmacologically expected, dose-related, and reversible on cessation as B cells repopulated from CD20-negative progenitors.

Species selection and cross-reactivity. Tissue cross-reactivity and antigen-binding studies established that the cynomolgus monkey is the sole pharmacologically and toxicologically relevant species; OBX-319 does not bind rodent CD19 or CD20, so rodents are not relevant and no homologous surrogate or transgenic approach was required. This selection is consistent with ICH S6(R1), which directs safety assessment to pharmacologically responsive species.

Safety pharmacology. Cardiovascular, respiratory, and central-nervous-system endpoints were incorporated into the repeat-dose cynomolgus studies rather than conducted as stand-alone assessments, in line with ICH S6(R1). Given that OBX-319 is a large, target-specific IgG1 with no expected interaction with ion channels or small-molecule pharmacology, dedicated in vitro hERG assessment and a stand-alone thorough-QT study are not warranted.

Pharmacokinetics/toxicokinetics. In the cynomolgus monkey, SC administration showed absorption consistent with IgG bioavailability and systemic disposition dominated by target-mediated drug disposition (TMDD): non-linear, dose-dependent clearance at concentrations where target engagement is not saturated, transitioning to linear catabolic elimination at higher exposures. Toxicokinetic exposure (AUC and Cmax) increased with dose and supported the NOAEL-based margins referenced above.

Toxicology. Repeat-dose GLP toxicology in the cynomolgus monkey with a recovery phase characterized findings that were an anticipated consequence of pharmacology: sustained peripheral and lymphoid B-cell depletion, decreased serum immunoglobulins, and diminished T-cell-dependent antibody responses, without unexpected target-organ toxicity. These changes were partially to fully reversible during recovery in parallel with B-cell repopulation. Anti-drug antibody (ADA) formation was observed in animals and, as expected, is of limited predictive value for human immunogenicity but was accounted for in exposure interpretation. Consistent with ICH S6(R1), standard genotoxicity and carcinogenicity studies are not warranted for a monoclonal antibody of this class; the potential effects of prolonged immunomodulation are addressed through pharmacology, the depletion/repopulation profile, and clinical pharmacovigilance rather than rodent bioassays. Reproductive and developmental risk reflects known IgG1 class behaviour, including active placental transfer during the second and third trimesters with the potential for B-cell depletion in the offspring; this is managed through labelling and contraception guidance rather than by studies in a non-cross-reactive species.

5 Effects in Humans

Pharmacokinetics. Subcutaneous absorption with typical IgG bioavailability; target-mediated drug disposition (TMDD) producing non-linear PK at low concentrations; distribution largely confined to plasma and interstitial fluid; elimination by proteolytic catabolism and (in the target-mediated component) receptor-mediated clearance. Classical small-molecule ADME (mass balance, CYP/transporter) is not applicable to an intact IgG. At exposures that saturate B-cell target, clearance approaches a linear, catabolic profile; as circulating drug declines and target re-emerges with B-cell repopulation, TMDD again contributes to non-linear elimination.

Pharmacodynamics and biomarkers. OBX-319 produced rapid, near-complete depletion of circulating CD19-positive B cells on both active arms (approximately 210 down to approximately 7 cells/µL), with no meaningful change on placebo. Depletion was accompanied by falls in anti-double-stranded-DNA (anti-dsDNA) antibody titres and normalization of complement C3 and C4 among responders, providing biologically coherent, mechanism-linked evidence of on-target activity that tracked with clinical response.

Immunogenicity. Anti-drug antibody (binding and neutralising) assessment is integral; immunogenicity may affect exposure and is characterised with a tiered validated assay strategy (screening, confirmatory, and titre, with a neutralising-antibody tier). Immunogenicity results are interpreted together with PK and B-cell pharmacodynamics to assess any impact on exposure, depletion, and safety.

Efficacy and safety observed in OBX319-301:

Study OBX319-301 was a Phase 3, randomized, double-blind, placebo-controlled trial that enrolled 480 subjects with moderate-to-severe active SLE (mean baseline SLEDAI-2K approximately 11), randomized 1:1:1 to OBX-319 High (n=162), OBX-319 Low (n=158), or placebo (n=160) on background standard-of-care over 52 weeks. The primary endpoint — SRI-4 response with low disease activity (SLEDAI-2K ≤ 4) at Week 52 — was met: 52.4% (76/145) on High, 33.8% (49/145) on Low, and 6.0% (9/150) on placebo. The key secondary endpoint of LS-mean change in SLEDAI-2K favoured both active arms over placebo, as summarized below.

Arm	N	LS-mean Δ SLEDAI-2K @ Wk 52 (points)	Diff vs placebo (95% CI)	p
OBX-319 High	162	-6.37	-2.91 (-3.12, -2.69)	0.0000
OBX-319 Low	158	-5.62	-2.17 (-2.38, -1.95)	0.0000
Placebo	160	-3.46	— (reference)	—

Safety was consistent with the known pharmacology of B-cell depletion. The most important identified risks for this class are serious and opportunistic infections and hypogammaglobulinaemia arising from sustained B-cell depletion and reduced immunoglobulins; injection reactions and immunogenicity are expected events. Overall treatment-emergent adverse event (TEAE) frequencies were broadly comparable across arms, with a small excess of serious adverse events on the High arm; deaths were rare and no single arm showed an unexpected pattern.

Arm	N	≥1 TEAE	SAE	Deaths	Discontinued
OBX-319 High	162	78	2	1	17
OBX-319 Low	158	74	1	0	13
Placebo	160	78	1	0	10

7 Guidance for the Investigator

Dosing, monitoring, and risk management follow the protocol and the reference safety information.

Administration. OBX-319 is given by subcutaneous injection per the protocol dosing schedule. Investigators should observe subjects after early injections for injection-site and systemic administration reactions and manage per institutional standards; premedication may be applied according to the protocol.

Screening and risk mitigation. Before initiating therapy, screen for and manage active or latent infection, including hepatitis B and C and tuberculosis, and complete indicated immunizations in advance because response to vaccination may be blunted during B-cell depletion. Live or live-attenuated vaccines should not be given during treatment.

Monitoring. Monitor for signs and symptoms of infection throughout treatment and during the period of B-cell depletion, and evaluate serum immunoglobulins (in particular IgG) periodically; persistent or symptomatic hypogammaglobulinaemia and serious or opportunistic infection should prompt clinical intervention and consideration of dosing interruption per the protocol. Assessment of B-cell counts and, where informative, ADA and disease biomarkers (anti-dsDNA, complement C3/C4) supports interpretation of response and safety.

Special populations. Given active placental transfer of IgG1, women of childbearing potential should use effective contraception per the protocol, and B-cell status of exposed infants should be considered where relevant. The overall risk profile is that of B-cell-depleting therapy; monitoring is directed at infection and immunoglobulin surveillance rather than the class-specific risks of unrelated therapeutic modalities.

ICH E6(R3).